Yoseph Shaaltiel - Protalix BioTherapeutics Insider

PLX -- Israel Stock  

ILS 161.20  7.80  5.08%

Founder and Executive VP of RandD
Dr. Yoseph Shaaltiel, Ph.D., is Executive Vice President Research Development of the Protalix Biotherapeutics Inc. He founded Protalix Ltd. in 1993 and has served as our Executive Vice President, Research and Development since December 2006. From 2006 through 2014, he served on our Board of Directors. Prior to establishing Protalix Ltd., from 1988 to 1993, Dr. Shaaltiel was a Research Associate at the MIGAL Technological Center. He also served as Deputy Head of the Biology Department of the Biological and Chemical Center of the Israeli Defense Forces and as a Biochemist at Makor Chemicals Ltd. Dr. Shaaltiel was a Postdoctoral Fellow at the University of California at Berkeley and at Rutgers University in New Jersey. He has coauthored over 40 articles and abstracts on plant biochemistry and holds several patents
Age: 63  Founder Since 2016  Ph.D    
972 4 988 9488  http://www.protalix.com
Shaaltiel received his Ph.D. in Plant Biochemistry from the Weizmann Institute of Science, an M.Sc. in Biochemistry from the Hebrew University and a B.Sc. in Biology from the Ben Gurion University.

Management Efficiency

The company has return on total asset (ROA) of (34.12) % which means that it has lost $34.12 on every $100 spent on asset. This is way below average.
The company has accumulated 52.04 M in total debt. Protalix BioTherapeutics has Current Ratio of 2.54 suggesting that it is liquid and has the ability to pay its financial obligations in time and when they become due.

Entity Summary

Protalix BioTherapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system in Israel and internationally. Protalix BioTherapeutics, Inc. was founded in 1993 and is based in Karmiel, Israel. Protalix BioTherapeutics operates under Biotechnology classification in Israel and traded on Tel Aviv Stock Exchange. It employs 190 people.Protalix BioTherapeutics (PLX) is traded on Tel Aviv Stock Exchange in Israel. It is located in 2 Snunit Street and employs 190 people.

Protalix BioTherapeutics Leadership Team

Roger Kornberg, Director, Ph.D
Yoseph Shaaltiel, Founder, Ph.D
Shlomo Yanai, Chairman, Ph.D
Yaron Naos, President, MBA
Amos BarShalev, Director, MBA
Tzvi Palash, COO
Aharon Schwartz, Director, Ph.D
Zeev Bronfeld, Chairman
Einat Almon, SVP, Ph.D
Yossi Maimon, President, MBA
Marcy Nanus, Executive
Moshe Manor, CEO, MBA
Yodfat Buchris, Director, MBA

Stock Performance Indicators

Current Sentiment - PLX

Protalix BioTherapeutics Investor Sentiment
Most of Macroaxis users are at this time bullish on Protalix BioTherapeutics. What is your perspective on investing in Protalix BioTherapeutics? Are you bullish or bearish?
98% Bullish
2% Bearish
Currently Active Assets on Macroaxis
Purchased over 100 shares of
few hours ago
Traded for 25.35
Purchased over 500 shares of
few hours ago
Traded for 5.66
Purchased few shares of
few hours ago
Traded for 1188.8199
Purchased over 70 shares of
few hours ago
Traded for 39.36
Purchased few shares of
few hours ago
Traded for 1188.8199
Additionally take a look at Your Equity Center. Please also try World Markets Correlation module to find global opportunities by holding instruments from different markets.